Prices paid for adult and paediatric antiretroviral treatment by low- and middle-income countries in 2012: High, low or just right?

Antiviral Therapy

Volumn 19, Issue , 2014, Pages 39-47

  Perriëns, Joseph H ^a   Habiyambere, Vincent ^a   Dongmo Nguimfack, Boniface ^a   Hirnschall, Gottfried ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE PLUS NEVIRAPINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GENERIC DRUG;

ADULT; CHILD; DRUG COST; DRUG FORMULATION; DRUG MARKETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWEST INCOME GROUP; PRACTICE GUIDELINE; REVIEW; SCALE UP; WORLD HEALTH ORGANIZATION; COMMERCIAL PHENOMENA; DEVELOPING COUNTRY; DRUG INDUSTRY; ECONOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; INCOME; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; COMMERCE; DEVELOPING COUNTRIES; DRUG INDUSTRY; DRUGS, GENERIC; GUIDELINES AS TOPIC; HIV INFECTIONS; HUMANS; INCOME; WORLD HEALTH ORGANIZATION;

EID: 84922203414     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2899     Document Type: Review

References (20)

1. World Health Organization, UNICEF and UNAIDS. Global update on HIV treatment 2013: results, impact and opportunities. (Updated June 2013. Accessed 7 July 2014.) Available from http://www.who.int/hiv/pub/progressreports/update2013/en/index.html
2. UNAIDS. Ten targets. 2011 United Nations General Assembly political declaration on HIV/AIDS: targets and elimination commitments. (Accessed 14 September 2012.) Available from http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2262-UNAIDS-ten-targets-en.pdf
3. World Health Organization. The global price reporting mechanism for HIV, tuberculosis and malaria. Database. (Accessed 14 January 2013.) Available from http://apps. who.int/hiv/amds/price/hdd
4. UNITAID. HIV, tuberculosis and malaria medicines landscape. Progress report on emerging issues and potential opportunities to improve access. (Accessed 31 March 2013.) Available from http://www.unitaid.eu/marketdynamics/medicines-landscape
5. World Health Organization. Global forecasts of antiretroviral demand 2012-2013: joint WHO/UNAIDS annual consultation with pharmaceutical companies. (Accessed 31 March 2013.) Available from http://www.who. int/hiv/pub/meetingreports/consultation-pharmaceutical-companies/en/index.html
6. Habiyambere V. WHO Survey on ARV and diagnostic use 2012. Preliminary results. (Accessed 31 March 2013.) Available from http://www.who.int/entity/hiv/amds/1-PP7.pdf
7. WHO. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach: 2010 revision. Annex E: WHO, Geneva, 2010. (Accessed 31 March 2013.) Available from http://www.who.int/entity/hiv/pub/paediatric/paediatric-arv-dosing.pdf
8. WHO. Sources and prices of active pharmaceutical ingredients. March 2005. (Accessed 31 March 2013.) Available from http://www.who.int/entity/hiv/pub/amds/api2005.pdf
9. WHO. Sources and prices of active pharmaceutical ingredients. 2007. (Accessed 31 March 2013.) Available from http://www.who.int/entity/hiv/topics/api2007.pdf
10. WHO. Sources, quality and prices of active pharmaceutical ingredients of antiretroviral drugs: results of a 2010 WHO survey. WHO, Geneva, 2011. (Accessed 31 March 2013.) Available from http://apps.who.int/iris/bitstream/10665/44799/1/9789241503099-eng.pdf
11. WHO. Sources, quality and prices of active pharmaceutical ingredients of antiretroviral drugs. Results of a 2012 WHO survey. (Accessed 31 March 2013.) Available from http://apps.who.int/iris/bitstream/10665/75172/1/9789241503778-eng.pdf
12. Pinheiro E, Vasan A, Kim JY, Lee E, Guimier JM, Perriens J. Examining the production costs of antiretroviral drugs. AIDS 2006;20:1745-1752.
13. WHO. Transaction prices for antiretroviral medicines and HIV diagnostics from 2004 to September 2008. (Accessed 7 July 2014.) Available from http://www.who.int/hiv/amds/GPRMsummaryReportOct2008.pdf
14. WHO. Transaction prices for antiretroviral medicines from 2009 to 2012. Summary report December 2012. (Accessed 7 July 2014.) Available from http://apps.who.int/hiv/pub/amds/gprm2012/en/index.html
15. WHO. Transaction prices for antiretroviral medicines from 2010 to 2013: WHO AIDS medicines and diagnostics services: global price reporting mechanism summary report, December 2013. (Accessed 7 July 2014.) Available from http://apps.who.int/hiv/pub/amds/amds-globalpricereport/en/index.html
16. WHO, UNICEF, UNAIDS. Progress report 2011: global HIV/AIDS response. Epidemic update and health sector progress towards universal access. (Accessed 31 March 2013.) Available from http://whqlibdoc.who.int/publications/2011/9789241502986-eng.pdf
17. Médecins Sans Frontières. Untangling the web of antiretroviral price reductions. 14th Edition, July 2011. (Accessed 31 March 2013.) Available from http://www.msfaccess.org/sites/default/files/MSF-assets/HIV-AIDS/Docs/AIDS-report-UTW14-ENG-2011-FINAL3.pdf
18. World Health Organization. Antiretroviral medicines in low- and middle-income countries: forecasts of global and regional demand for 2012-2015. (Accessed 7 July 2014.) Available from http://apps.who.int/iris/bitstream/10665/83148/1/9789241505468-eng.pdf
19. Dehne K. Financing ART in low and middle-income countries. (Accessed 31 March 2013.) Available from http://www.who.int/entity/hiv/amds/1-PP11.pdf
20. Nakakeeto ON, Eliot B. Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market. Global Health 2013;9:6.